Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.15 EUR
Change Today +0.005 / 0.44%
Volume 0.0
TEHN On Other Exchanges
As of 3:00 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - €1.51
52 Week Low
10/13/14 - €0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals, Inc. Receives New Patent for Cancer Drug from European Patent Office

Peregrine Pharmaceuticals, Inc. received a new patent from the European Patent Office (EPO), titled, Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel. The new patent covers bavituximab as a composition of matter, a range of related antibodies, including humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies. This patent currently provides intellectual property rights in validated European countries through July, 2023 and could be eligible for extension of patent term under the European Union's Supplementary Protection Certificate (SPC) process. This patent was granted to The University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals. Peregrine's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer (the SUNRISE trial) along with several investigator-sponsored trials evaluating additional oncology indications. The Company is also advancing its plans to initiate additional bavituximab clinical trials, including a Phase II trial in non-small cell lung cancer in combination with Opdivo (Nivolumab) and a Phase II/III trial in locally advanced or metastatic HER2 negative breast cancer in combination with either docetaxel or paclitaxel.

Peregrine Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 03:45 PM

Peregrine Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 03:45 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Stephen Worsley, Vice President, Business Development.

Peregrine Pharmaceuticals, Inc. Declares Quarterly Dividend on its Series E Convertible Preferred Stock, Payable on July 1, 2015

Peregrine Pharmaceuticals, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on July 1, 2015 to holders of record at the close of business on June 19, 2015. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from April 1, 2015 through June 30, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.15 EUR +0.005

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $23.57 USD +0.33
GenVec Inc $2.04 USD -0.05
Inovio Pharmaceuticals Inc $7.92 USD -0.22
Progenics Pharmaceuticals Inc $6.97 USD -0.12
Vical Inc $0.70 USD +0.0149
View Industry Companies

Industry Analysis


Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at